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Accumulation of carboxy-terminal fragments of parathyroid hormone-
related protein in renal failure. We have recently demonstrated elevations
of separate amino- and carboxy-terminal parathyroid hormone-related
protein (PTHrP) fragments in patients with humoral hypercalcemia of
malignancy (HHM) using both a two-site immunoradiometric assay
(IRMA) with amino-terminal specificity for PTHrP, and with a carboxy-
terminal radioimmunoassay (RIA) for PTHrP(109-138). PTHrP(l09-138)
immunoactivity from plasma of patients with HHM could not be
extracted using an amino-terminal PTHrP immunoaffinity column,
indicating that the carboxy-terminal region circulates as a discrete
peptide. Carboxy-terminal immunoreactive (i) PTHrP levels were also
elevated in normocalcemic patients with chronic renal failure (without
cancer), whereas amino-terminal iPTHrP levels were normal in patients
with renal failure. In order to further define the renal handling of
carboxy-terminal PTHrP peptides, we have evaluated circulating
iPTHrP(109-138) concentrations in patients with a wide range of renal
function. We studied 25 patients with abnormal renal function of
diverse etiologies whose creatinine clearances ranged from 66 mI/mm to
less than 5 mI/mm. All patients had undetectable or low (2 pmol/liter)
concentrations of iPTHrP(l-74). iPTHrP(l09-138) concentrations were
undetectable in patients with creatinine clearances 20 mI/mm, but
became elevated in patients with creatinine clearances <20 mI/mm. The
log of iPTHrP(109-138) correlated negatively with the log of creatinine
clearance (r = 0.88, P = 0.0001). Mean iPTHrP(109-138) levels were
slightly higher for patients on hemodialysis (32.7 3.1 pM) than for
those on chronic ambulatory peritoneal dialysis (22.1 3.4 pM; P <
0.05), suggesting that some carboxy-terminal PTHrP fragments may be
cleared to a greater extent by the peritoneal membrane. Gel filtration
chromatography was performed using Sephadex G-50 and Sephacryl
S-200 columns to further characterize the carboxy-terminal PTHrP
fragments. Plasma immunoactivity from normo-calcemic dialysis pa-
tients eluted largely as a single peak on both columns in a position
similar to that for plasma from patients with HHM. However, because
of anomalous elution of the PTHrP(109-138) standard, an accurate
assessment of the molecular weight of this fragment could not be
performed. We conclude that carboxy-terminal iPTHrPs are present in
the plasma of patients with renal failure but without cancer, and that
these carboxy-terminal fragments depend on glomerular ifitration for
clearance. Gel filtration chromatography indicates that the carboxy-
terminal iPTHrP fragment circulating in patients with renal insufficiency
appears to be similar or identical to the carboxy-terminal fragment
which circulates in patients with humoral hypercalcemia of malignancy.
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Parathyroid hormone-related protein (PTHrP), which is re-
sponsible for the syndrome of humoral hypercalcemia of malig-
nancy (HHM), has been purified and molecularly cloned [1—51.
Synthetic and recombinant PTHrP analogs reproduce many of
the biochemical features of HHM through their interaction with
PTH receptors in bone and kidney [61. Perhaps the most
compelling evidence that PTHrP plays a causative role in HHM
is the observation that infusion of PTHrP-specific antisera into
mouse and rat models bearing HHM-associated tumors can
normalize the hypercalcemia and elevations in urinary cyclic
AMP [71. The development of sensitive immunoassays for
PTHrP has confirmed that circulating PTHrP levels are elevated
in the majority of patients with malignancy-associated hyper-
calcemia [8—111, and in most patients with HHM defined by
strict biochemical criteria [91.
PTHrP shares primary amino acid sequence homology with
parathyroid hormone (PTH) at its extreme amino-terminus,
thereafter diverging completely [61. Several potential proteo-
lytic cleavage and amidation sites have been identified within
the unique cDNA-predicted PTHrP sequence [4, 12, 13], sug-
gesting that post-translational modification or post-secretory
peripheral degradation may occur. We have recently demon-
strated elevations of separate amino- and carboxy-terminal
immunoreactive (i) PTHrP fragments in patients with HHM
using both a two-site immunoradiometric assay (IRMA) with
amino-terminal specificity [PTHrP(1-74)} as well as with a
carboxy-terminal-specific radioimmunoassay (RIA) for PTHrP
(109-138) [9]. An amino-terminal PTHrP immunoaffinity column
failed to extract PTHrP(109-138) immunoactivity from the plasma
of HHM patients, indicating that carboxy-terminal PTHrPs circu-
late as peptides discrete from the amino-terminal region [91. In the
same report, we demonstrated that carboxy-terminal iPTHrP
levels were elevated in normocalcemic patients with chronic renal
failure (CRF) but without cancer. In contrast to patients with
HHM, amino-terminal iPTHrP levels were normal in patients with
renal failure. Although PTHrP appears to be widely expressed in
a host of normal, non-malignant tissues [14—17], this was and
remains the only demonstration that PTHrP peptides enter the
circulation in patients without cancer. To further define the renal
handling of carboxy-terminal PTHrP peptides, we evaluated cir-
culating iPTHrP(109-l38) concentrations in patients with a wide
range of renal function, and have partially characterized these
fragments by gel filtration chromatography. The results suggest
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that C-terminal PTHrP fragments are cleared primarily by glomer-
ular filtration and confirm that these fragments accumulate in
severe renal failure.
Methods
Patients and samples
Plasma was obtained from 25 normocalcemic patients with-
out cancer with varying degrees of renal insufficiency, ranging
from near-normal renal function to dialysis-dependent. Creati-
nine clearance was determined from 24-hour urine collections.
In functionally anephric, hemodialysis-dependent patients, a
nominal value for creatinine clearance of 2 ml/min was as-
signed. As indicated in the Results section, additional patients
were studied under specific circumstances including acute renal
failure, renal transplantation, and chronic ambulatory perito-
neal dialysis. For comparative purposes, plasma was also
obtained from five patients with the typical clinical and bio-
chemical features of HHM [9, 13]. Plasma iPTHrP, as deter-
mined by IRMA and RIA (see below) was markedly elevated in
all five patients, as was nephrogenous or urinary cAMP. Each
had normal serum creatinine values.
Blood was drawn into iced, heparinized 10 ml tubes contain-
ing 500 d of the following protease inhibitor mixture: aprotinin
(500 KIU/ml), leupeptin (5 jxg/ml), pepstatin (5 /.LgIml), and
EDTA (1 mM). Samples were transported on ice, centrifuged at
4°C, and the plasma separated and stored at —70°C until use.
The stability of iodinated PTHrP(1- 141) in such heparinized
plasma was documented by incubating 30,000 cpm of iodinated
peptide with normal plasma at 4°C for 24 hours, and subsequent
analysis by SDS-PAGE and autoradiography [18, 19].
PTHrP(1-74) immunoradiometric assay (IRMA)
The two-site immunoradiometric assay is a sandwich-type
assay employing affinity-purified anti-PTHrP(37-74) as the cap-
ture antibody bound to a solid phase, and radiolabeled anti-
PTHrP(l-36) as the signal antibody [9]. The assay uses 200 pI
plasma samples which were collected on ice in the presence of
protease inhibitors, as previously described [9]. The sensitivity
of the IRMA is 0.2 fmol hPTHrP(1-74) per 200 d sample (1 pM).
This assay is equipotent for hPTHrP(1-108) and hPTHrP(l-14l),
and there is no cross reactivity with hPTH(l-84) [9].
PTHrP(109-138) radioiminunoassay (RIA)
Peptides and antisera
(Tyr36)hPTHrP(1-36)NH2 [referred to as PTHrP(1-36)],
hPTHrP(1-74), hPTHrP(37-74)], and (Tyr'°9)hPTHrP(109- 138)
[referred to as PTHrP(109-138)] were prepared by solid-phase
synthesis as previously described [20]. Recombinant
hPTHrP(1-141) was generously provided by R. Glenn Ham-
monds (Genentech, Inc., So. San Francisco, California, USA).
Radioiodination of peptides and purification by HPLC was
performed as described previously [21].
Immunization of New Zealand white rabbits was accom-
plished by subcutaneously injecting peptides which were con-
jugated to keyhole limpet hemocyanin and emulsified in Fre-
und's adjuvant [9]. Antiserum R-14, derived from a rabbit
immunized with PTHrP(1-74), was used to prepare affinity-
purified anti-PTHrP(1-36) and anti-PTHrP(37-74) antibodies for
the amino-terminal immunoradiometric (IRMA) assay as previ-
ously described [9]. Affinity-purified anti-PTHrP(1-36) antibod-
ies were radiolabeled by a variation of the tactoperoxidase
method (Enzymobeads, Bio-Rad, Richmond, California, USA)
[9]. An anti-PTHrP(1-36) immunoaffinity column was prepared
by covalently coupling affinity-purified anti-PTHrP(l-36) to
protein A-Sepharose CL-4B (Pharmacia) [9]. Antiserum R-22,
derived from a rabbit immunized with (Tyr'®)hPTHrP(109-
138), was used for the carboxy-terminal radioimmunoassay
(RIA) [9].
This traditional radioimmunoassay utilizes 1251(Tyr'°9)hPTHrP
(109-138) as radioligand and 100 1.d of unextracted plasma as
previously described [9]. The detection limit for (Tyr109)hPTHrP
(109-138) is 0.2 fmol per 100 .d sample (2 pM), and there is no
cross reactivity with hPTH(1-84). hPTHrP(107-138) is equipo-
tent with (Tyr109)hPTHrP(109-138) in this assay.
We have previously shown that the RIA for PTHrP(109-138)
does not recognize amino-terminal PTHrP peptides and has no
cross reactivity with PTH [9]. Elevated carboxy-terminal
iPTHrP fragments were detected in patients with HHM and in
patients with CRF on dialysis [9]. The ability of the carboxy-
terminal antiserum to recognize intact, full-length, recombinant
PTHrP(1-14 1) is shown in Figure 1. Surprisingly, the carboxy-
terminal antiserum recognizes carboxy-terminal PTHrP frag-
ments approximately 200x better than the intact parent pep-
tide. These findings further support our previous studies in
patients with HHM and CRF [9, 18] which indicated that
carboxy-terminal fragments of PTHrP circulate in these two
conditions.
Chromatography
Gel filtration was performed on a 87 x 2 cm Sephadex G-50
SF (Pharmacia, Piscataway, New Jersey, USA) column run in
100 mM ammonium bicarbonate (pH 9.0) with 0.1% BSA at 4°C
as described [18]. BSA was added to the mobile phase to
minimize the interaction of PTHrP with the solid phase and to
100
80
60040
20
0
Peptide concentration, PM
Fig. 1. Assay sensitivity and specificity for the PTHrP(lO9-l38) radio-
immunoassay. Displacement of radioligand is shown as a function of
concentration of (Tyr'°9)hPTHrP(109-l38) (I), andhPTHrP(l-14l) (0).
B/Bo represents the ratio of specific binding of sample to the specific
binding of the zero standard.
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maximize recovery of PTHrP. Samples consisted of 2.5ml of
patient plasma combined with 2.5 ml 200 mM ammonium
bicarbonate. Five ml fractions were collected. These fractions
were lyophilized, resuspended in 500 1 PBT buffer (10 mM
phosphate-buffered saline (pH 7.4), 0.1% BSA, 0.1% Triton
X-l00), and stored at —70°C until later analysis in the RIA. Mr
markers were ferritin (440 k), albumin (68 k), myoglobin (17 k),
cytochrome C (12.3 k), PTHrP(l-74) (8.5 k), PTHrP(1-36) (4.3
k), PTHrP(109-l38) (3.1 k), and tetracycline (0.25 k).
Plasma was also chromatographed on a 1.7 x 120 cm
Sephacryl S-200 SF (Pharmacia) column in 100 mrvi NH4HCO3
(pH 9.0), containing 0.01% BSA at 4°C as described [181.
Plasma (2.5 ml) was mixed with 2.5 ml ice-cold column buffer
and centrifuged at 7000 x g for 15 minutes at 4°C, and then
applied to the column. Five ml fractions were collected, frozen,
lyophilized, and stored at —70°C until assay.
Results
To further define the degree of renal insufficiency required to
elicit elevations of circulating C-terminal iPTHrP fragments, we
measured iPTHrP(109-138) levels in 25 patients with abnormal
renal function of diverse etiologies whose creatinine clearances
(Ccr) ranged from 66 mI/mm to <5 mI/mm (Fig. 2). A highly
significant (P = 0.0001) negative correlation between the log of
iPTHrP(109-138) and the log of creatinine clearance (Ccr) was
observed. Elevated levels were detectable only in patients with
Cr <20 mi/mm (Fig. 2).
To determine whether differential clearance of C-terminal
iPTHrP fragments occurred across the peritoneal membrane as
compared to the hemodialysis membrane, eleven patients on
chronic ambulatory peritoneal dialysis (CAPD) were evaluated
separately and compared to 21 randomly-selected hemodialysis
patients in the same assay (Fig. 3). The mean iPTHrP(109-138)
level for CAPD patients was somewhat lower (22.1 3.4 pM)
than for hemodialysis patients (32.7 3.1 pM; P < 0.05).
iPTHrP(l-74) levels were undetectable in all patients from both
groups. Samples for hemodialysis patients were obtained pre-
dialysis; no significant differences were observed when com-
pared to post-dialysis samples (data not shown). Two other
patients evaluated separately were followed longitudinally
through their illnesses. The first patient was receiving hemodi-
alysis for CRF and had a baseline iPTHrP(109-138) level of 15
p. Seven days after receiving a successful kidney transplant,
the iPTHrP(109-l38) level was undetectable. In a second patient
who developed adrenal insufficiency secondary to bilateral
adrenal hemorrhage resulting in hypotensive acute renal failure
(ARF), the iPTHrP(109-138) level rose from an undetectable
level before ARF to 14 M on day 5 following the episode (Cr =
2.4).
Gel filtration studies were performed on CRF plasma using a
Sephadex G-50 SF column (pH 9.0) (Fig. 4). Plasma samples
from six normocalcemic dialysis patients and one patient with
HHM were chromatographed under these basic, non-denatur-
ing conditions, and the fractions were assayed for PTHrP(109-
138) immunoreactivity. The elution positions of radioiodinated
PTHrP(l-141), (1-74), (109-138), and (1-36) are shown. Immu-
noactivity in all six renal failure samples eluted largely as a
single peak in a position similar to that for the one patient with
HHM, suggesting that the Mr of the circulating carboxy-
terminal PTHrP fragment was approximately 8000. This molec-
ular weight, however, is considered tentative because of the
anomalous elution of the PTHrP(109-138) standard.
Carboxy-terminal immunoactivity was also examined in
plasma chromatographed on a Sephacryl S-200 SF column at
pH 9.0 (Fig. 5). Labeled PTHrP(l-l4l) eluted in its expected
position, comigrating with myoglobin and running ahead of
cytochrome C. Labeled PTHrP(1-74) and PTHrP(1-36) also
migrated in their expected positions (8.5 k and 4.3 k, respec-
tively). Again, labeled PTHrP(109-138) (actual Mr = 3114)
eluted anomalously on this column in a position ahead of
PTHrP(1-74), and similar to cytochrome C (Mr = 12 k). Plasma
from two patients with CRF was compared to the mean values
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Fig. 2. Levels of iPTHrP(109-138) (pMEq) determined by RIA are
plotted vs. creatinine clearance (mi/mm) in 25 normocalcemic patients
without cancer. All patients had undetectable or low (<2 pM) levels of
iPTHrP(1-74) by immunoradiometric assay. Inset: linearization of same
data on a log-log plot. Log(PTHrP) = 1.6 — (0.8) Log (Ce,.), r = 0.88.
HO CAPD
Fig. 3. Comparison of iPTHrP(109-138) (pMEq) levels determined by
RIA in twenty-one patients on hemodialysis (HD) and in eleven patients
on chronic ambulato,y peritoneal dialysis (CAPD), All samples were
run in duplicate in the same assay. Bars indicate mean values for each
group (P < 0.05).
Im
m
un
or
ea
ct
iv
e 
hP
TH
rP
 (1
09
—
13
8) 
-
 
Eq
 
a
 
o
 
0 
0 
0 
0 
-
S 
I 
01
• 
.
_
—
 
17
k 
(31
 
?!
 
=
=
 
a
—
 8.
5 
k 
(,)
 
a
—
l0
9-
l3
8 
01
 
a
 ('I 
a
—
 4
.3
k 
01
 
01
 
a
_
—
Vs
 
Im
m
un
or
ea
ct
iv
e 
hP
TH
rP
 (1
09
—
1 3
8) 
-
 
Eq
 
0 
0 
g 
a
—
68
k 
•
 
.
 
a
—
17
k 
18
9—
13
8 
-
 
a
—
8.
5k
 
a
—
 4
.3
k 
a
—
 V
s 
1374 Or/off et a!: Carboxy-terminal PTHrP in renal failure
Fig. 4. Ge/filtration profiles of plasma from a representative patient
with CRF on dialysis (D) and one patient with HHM (•) on a Sephadex
G-50 SF column, pH 9.0. The gel filtration profiles for five additional
patients with CRF were similar, but are not shown for the purpose of
clarity. The elution positions of radiolabeled PTHrP peptides are
marked. Note the surprisingly disparate elution positions of PTHrP(l-
36) (actual Mr = 4.3 k) and PTHrP(109-138) (actual Mr = 3.1 k) on this
column.
for five patients with HHM reported previously [18] (Fig. 5). A
single major peak of immunoactivity was observed for all
samples eluting in a position between myoglobin and cyto-
chrome C. Accurate assessment of Mr, however, is hampered
by the surprisingly large apparent Mr of PTHrP(109- 138), which
coeluted with the 12,000 Mr marker.
Discussion
This study documents the presence of iPTHrP peptides in the
circulation of patients without cancer, and the accumulation of
carboxy-terminal fragments of PTHrP in severe renal insuffi-
ciency. The strong negative correlation between the logarithm
of the carboxy-terminal iPTHrP concentration and creatinine
clearance suggests that these fragments are cleared primarily by
glomerular filtration. This relationship is highly analogous to
that for carboxy-terminal fragments of iPTH [22—26], although
there is no sequence homology between these proteins in this
region. Carboxy-terminal iPTH peptides are generated in the
parathyroid gland [24], in the liver [22—24], and in the kidney
[23] by metabolism of intact hormone, are excreted by the
kidneys, and are known to accumulate in renal insufficiency
[22—26]. The excretion of carboxy-terminal iPTHrP peptides
into the urine of hypercalcemic and normocalcemic patients
with cancer has recently been reported by Imamura et al [27].
However, our study documents the release of PTHrP peptides
into the circulation of otherwise normal adults, which are
detectable only when the creatinine clearance is less than
approximately 20 mI/mm. Similar data exist for the clearance of
carboxy-terminal iPTH fragments as a function of renal clear-
ance. Both in the isolated perfused dog kidney [25] and in dog
Fig. 5. Gel filtration profiles on a Sephacryl 5-200 SF column (pH 9.0)
of plasma from two patients with CRF on dialysis (A, 0) and from five
patients with HHM (•), whose mean values for iPTHrP(109-138) are
shown. The column markers are bovine albumin (68 k), myoglobin (17
k), cytochrome C (12 k) [which coeluted with PTHrP(l09-138)],
PTHrP(1-74) (8 k), and PTHrP(1-36) (4.3 k). Note that C-terminal
PTFIrP immunoactivity elutes as a single peak between the 17 k and 12
k markers for both HHM and CRF patients. Note that synthetic
PTHrP(109-138) also elutes in an anomalous position on this column,
coeluting with cytochrome C (12 k).
studies in vivo [26], C-terminal iPTH peptides increase when
GFR falls below 40 mi/mm. Whether equimolar quantities of
amino-terminal PTHrP peptides are also secreted into the
circulation of patients without cancer, and then rapidly metab-
olized, remains to be determined.
PTHrP is widely expressed by a host of normal tissues
[14—17], and the present data support a growing body of
literature that suggests a physiological role for PTHrP in normal
adults, presumably as a local autocrine or paracrine factor [6].
A provocative recent report indicates that a carboxy-terminal
peptide, PTHrP(l07-1 11) ("osteostatin"), may possess biolog-
ical properties that are distinct from those of the PTH-like
amino-terminus of PTHrP, namely to inhibit osteoclast-medi-
ated bone resorption [28]. While it is not known whether the
carboxy-terminal fragment detected by our assay includes this
region, it is conceivable that carboxy-terminal PTHrP frag-
ments which accumulate in renal failure play some systemic
role in the clinical expression of renal osteodystrophy, partic-
ularly in the context of the aplastic or low turnover form.
Because small peptide fragments may be cleared more effi-
ciently across the peritoneal membrane than the artificial he-
modialysis filter [29], we compared C-terminal iPTHrP levels in
CAPD patients with those in patients on hemodialysis.
iPTHrP(109-138) levels were somewhat lower in the CAPD
patients, suggesting that some clearance of C-terminal iPTHrP
fragments may be accomplished by the peritoneal membrane.
Since C-terminal iPTHrP levels in both CAPD and hemodialysis
may be lower than one might expect if there were no transport
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In summary, these studies indicate that carboxy-terminal
iPTHrPs are present in the plasma of patients with renal failure
but without cancer, and that these carboxy-terminal fragments
depend on glomerular filtration for clearance. Gel filtration
studies indicate that the single major peak of carboxy-terminal
PTHrP immunoreactivity in patients with renal insufficiency
appears to be similar or identical to the carboxy-terminal
fragment(s) which circulates in patients with HHM. Since a
recent report suggests that the carboxy-terminus of PTHrP may
be a potent inhibitor of osteoclastic bone resorption [28], the
accumulation of these fragments in severe renal failure may
have important implications for the pathogenesis of renal os-
teodystrophy (particularly the adynamic form) and its response
to treatment. The biological, biochemical, and pathophysiolog-
ical properties of the native circulating carboxy-terminal frag-
ment merit further investigation.
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138) levels appeared to be associated with the rise and fall of
serum creatinine. This further suggests that carboxy-terminal
iPTHrPs are cleared by glomerular filtration.
In an attempt to further define the circulating species of
C-terminal iPTHrP peptide(s) in patients with renal insuffi-
ciency, gel filtration studies were performed. Plasma samples
were chromatographed at pH 9.0, which is near the calculated
p1 of cDNA-predicted full-length PTHrPs [3—5, 31, 321 and the
measured basic p1 (>8.7) of tumor-derived PTHrPs [33]. Under
these alkaline, non-denaturing conditions, radioiodinated
PTHrP(l-l41), (1-74) and (1-36) all migrated with Mr's similar to
their calculated Mr's on both the Sephadex G-50 and Sephacryl
S-200 columns. Examination of the column fractions using the
PTHrP(109-138) RIA yielded a single major peak of immunoac-
tivity for all CRF patients on both columns which coeluted with
that for the carboxy-terminal immunoreactivity in HHM pa-
tients. Surprisingly, the apparent Mr of iodinated PTHrP(109-
138) was found to be aberrantly high on both the Sephadex G-50
and Sephacryl S-200 columns. This prevents accurate assess-
ment of Mr for the eluted carboxy-terminal immunoactivity in
plasma. Aberrant migration of PTHrPs by SDS-PAGE and by
western immunoblotting analysis has been previously noted
[31, 32], presumably due to the unusually basic p1 of PTHrP
peptides.
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